Is Buying Stock Like argenx SE (ARGX) After Such Increase Winning Strategy?

March 14, 2018 - By reb123z

The stock of argenx SE (NASDAQ:ARGX) is a huge mover today! The stock increased 4.99% or $4.04 during the last trading session, reaching $85. About 482,172 shares traded or 81.00% up from the average. argenx SE (NASDAQ:ARGX) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $2.74 billion company. It was reported on Mar, 14 by We have $87.55 PT which if reached, will make NASDAQ:ARGX worth $82.17M more.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: which released: “25 Stocks Moving In Friday’s Pre-Market Session” on December 15, 2017, also with their article: “28 Stocks Moving In Tuesday’s Pre-Market Session” published on January 30, 2018, published: “28 Stocks Moving In Monday’s Pre-Market Session” on January 29, 2018. More interesting news about argenx SE (NASDAQ:ARGX) were released by: and their article: “uniQure NV” published on December 03, 2015 as well as‘s news article titled: “No Shortage of Positive Retail Sector Surprises” with publication date: August 18, 2017.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.74 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: